As we all know, drug development is a lengthy, high-investment, and high-risk process. Before a new drug enters clinical trials, in-depth and systematic research during the non-clinical stage is crucial. Preclinical pharmacological efficacy assessment is a core component of this process. It involves studying the basic types of drugs, their mechanisms of action, selectivity, dose-response relationships, therapeutic effects, and adverse reactions. Toxicology studies cover general toxicity, acute toxicity, long-term toxicity, and special toxicity tests. Properly utilizing appropriate in vitro and in vivo models that reflect the essence of drug action and therapeutic characteristics provides assurance for the drug's entry into clinical trials.
In summary, preclinical pharmacological efficacy encompasses the following key aspects:
1. Mechanism of Action
Understanding how a drug exerts its effects after entering the body is essential. Knowledge of the mechanism of action allows us to evaluate the likelihood of a product's successful market entry through literature research. In practical work, we can assess the mechanism of action by considering the following:
⑴Extent of Research: Is there sufficient literature on this mechanism? Consider the quantity and quality of relevant research, the discovery timeline of the target, and the researchers involved.
⑵Existing Marketed Drugs: Has this mechanism been used successfully in marketed drugs? While this validates its potential for drug development, it also raises concerns about competition if other products are already on the market. Differentiation can still provide commercial value.
⑶Clinical Stage Competitors: Investigate other companies with drugs targeting the same mechanism. Phase III trials carry more weight than Phase II trials because they involve patient efficacy data. Additionally, a crowded clinical stage may indicate future competition from similar mechanism-based drugs. Focus on specific clinical efficacy data and adverse events.
2. Potency
Potency refers to a drug's effectiveness. Common indicators include IC50, EC50, tumor inhibition rates, and minimum inhibitory concentration (MIC). Let's delve into commonly used indicators for evaluating anticancer drugs:
⑴IC50 (Half-Maximal Inhibitory Concentration): At this concentration, a drug inhibits or kills half of the tested entities (enzymes, receptors, cells, etc.). IC50 is primarily used for in vitro efficacy descriptions.
⑵EC50 (Half-Maximal Effective Concentration): This concentration achieves 50% of the maximum biological effect. EC50 can describe both in vitro and in vivo data.
⑶Tumor Inhibition Rate: Typically measured in animal models, it quantifies the inhibition of tumor growth.
Using these potency indicators, we can roughly compare the efficacy of target drugs. However, direct comparisons are valid only when using the same experimental models. Keep in mind that biological assay errors can affect conclusions if data from different studies are not directly comparable.
3. Dose-Response Relationship
Generally, higher doses lead to better efficacy within a certain range. When aiming for the same therapeutic effect, minimizing the drug dose is desirable. Assessing the minimum effective concentration/dose and the half-maximal effective concentration/dose helps estimate the drug's effective dose range.
4. Selectivity
Selectivity examines a drug's preference for a specific target over others. The goal is to avoid off-target toxicity based on the mechanism. For instance, Bcl-2 inhibitors like APG-2575 and ABT-199 (marketed in the US) both target Bcl-2. While the latter has a head start, differentiation could still provide advantages for the former.
In conclusion, understanding preclinical pharmacological efficacy is crucial for successful drug development. Rigorous research, transparency, and adherence to scientific principles enhance preclinical studies without stifling creativity.
